10x Genomics, Inc. Class A Common Stock
TXG10x Genomics, Inc. Class A (TXG) is a biotechnology company specializing in genomics and single-cell analysis solutions. It develops and commercializes advanced instruments and reagents that enable researchers to analyze biological systems at high resolution, facilitating breakthroughs in areas such as cancer, immunology, and genetics. The company's technologies are used in academic, clinical, and industrial research to accelerate understanding of complex biological processes.
Company News
Global tumor transcriptomics market projected to grow from $6.02 billion in 2024 to $8.71 billion by 2030, driven by rising cancer prevalence and genomic sequencing advancements, with spatial transcriptomics emerging as a key technological trend.
Lancaster Investment Management acquired a new $7.27 million position in 10x Genomics during Q3 2025, purchasing 621,779 shares representing 3.1% of its assets under management.
10x Genomics reported a Q2 2024 loss of $0.32 per share, beating the Zacks Consensus Estimate of a $0.47 loss. The company's revenue of $153.1 million also surpassed estimates. However, the stock has underperformed the market so far this year.
Cathie Wood's ARK ETFs made significant portfolio adjustments, selling Teladoc shares, increasing CrowdStrike holdings, and reducing Tesla positions.
Cathie Wood's Ark Invest reduced its stake in Tesla by $8 million, despite a recent bullish outlook on the company's potential in the autonomous taxi sector.
